Comparative study between intralesional injection of MMR, BCG, and candida albicans antigen in treatment of multiple recalcitrant warts.

Author: AshryWalaa Mohamed Omar, EldahshanRamadan Mohamed, ElsaieMohamed L

Paper Details 
Original Abstract of the Article :
BACKGROUND: Cutaneous warts represent a challenging condition to treat. OBJECTIVE: To evaluate the safety and efficacy of intralesional injection of MMR (mumps, measles, and rubella) antigen, BCG (bacillus Calmette-Guerin) vaccine, and candida antigen for the treatment of multiple warts. METHODS: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/jocd.14737

データ提供:米国国立医学図書館(NLM)

Warts: A Comparative Study of Intralesional Treatments

Cutaneous warts, those annoying bumps that often appear on the skin, can be a stubborn problem. This research investigates the effectiveness of three different intralesional injections for treating recalcitrant warts, those that refuse to disappear easily. The study compared the efficacy of MMR (mumps, measles, and rubella) antigen, BCG (bacillus Calmette-Guerin) vaccine, and candida antigen in a randomized clinical trial, a method that ensures a fair comparison. The findings suggest that all three treatment modalities were effective, with MMR and BCG showing higher clearance rates than candida antigen. The researchers also highlighted the safety and minimal side effects associated with these treatments.

Intralesional Treatments: A Promising Avenue for Warts

The results of this study provide valuable insights into the potential benefits of intralesional injections for treating recalcitrant warts. While further research is needed to determine the optimal treatment approach for each patient, the study suggests that MMR, BCG, and candida antigen injections could be effective and well-tolerated options. The study also emphasizes the need for ongoing research to optimize the use of these treatments and explore other potential therapies for those who do not respond to the tested modalities.

Navigating the Desert of Warts

Treating warts can feel like navigating a desert of uncertainty. This study offers valuable knowledge to help guide us through the complexities of wart treatment. It reminds us that there are multiple paths to explore, and finding the right approach for each individual is key. It's essential to consult with a dermatologist for personalized advice and guidance to ensure the most effective treatment option. Remember, patience and perseverance are crucial when tackling stubborn desert challenges. The right approach can lead to clearer skin and a renewed sense of confidence.

Dr.Camel's Conclusion

This study offers hope for those struggling with recalcitrant warts, exploring the effectiveness of three different intralesional injection therapies. While all three treatments showed promising results, the study underscores the need for personalized treatment approaches and ongoing research to optimize the use of these therapies. This study is a valuable step in the ongoing quest to find effective and well-tolerated solutions for those seeking relief from the challenges of warts.

Date :
  1. Date Completed 2022-02-28
  2. Date Revised 2023-01-05
Further Info :

Pubmed ID

34998000

DOI: Digital Object Identifier

10.1111/jocd.14737

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.